Millions of girls in developing nations will avoid getting a deadly form of cancer---cervical cancer---due to a major drop in costs for two vaccines against cervical cancer. Merck and GlaxoSmithKline announced May 9 that costs for the vaccines against human papillomavirus (HPV) would be cut to below $5 per dose.
Over 275,000 women die from cervical cancer per year in poor countries.
Merck’s Gardasil vaccine will cost $4.50 per dose and GlaxoSmithKline’s Cervarix will cost $4.60 per dose. The costs were negotiated through the GAVI Alliance (see infographic).
This is welcome news, with cancers and other chronic diseases becoming one of global health’s biggest challenges, moving towards the post-Millennium Development Goals era.